Researchers at McGill University in Canada have devised a new artificial intelligence (AI) based approach to predict cognitive decline that may lead to Alzheimer’s disease over the next five years.

Led by McGill University psychiatry department assistant professor Mallar Chakravarty, the team designed and trained an algorithm to learn signatures from MRI, genetics and clinical data.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The researchers used data from more than 800 people under the Alzheimer’s Disease NeuroImaging Initiative. Participants included healthy individuals, people with mild cognitive impairment, and Alzheimer’s patients.

“At present, the researchers are working towards validating the algorithm’s accuracy using new data in order to improve predictions and assess its extent of detection.”

Findings from the study were then replicated on a separately obtained sample from the Australian Imaging and Biomarkers Lifestyle Study of Ageing.

It is expected that by predicting an individual’s cognitive decline towards Alzheimer’s, the algorithm will help in potentially early prevention and the right treatment for the disease.

Chakravarty said: “At the moment, there are limited ways to treat Alzheimer’s and the best evidence we have is for prevention. Our AI methodology could have significant implications as a ‘doctor’s assistant’ that would help stream people onto the right pathway for treatment.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“For example, one could even initiate lifestyle changes that may delay the beginning stages of Alzheimer’s or even prevent it altogether.”

At present, the researchers are working towards validating the algorithm’s accuracy using new data in order to improve predictions and assess its extent of detection.

The team hopes that more data will aid in the better identification of those at greatest risk for cognitive decline leading to Alzheimer’s.

The Alzheimer Society of Canada report revealed 564,000 Canadians suffering from Alzheimer’s or another form of dementia in 2016. This is estimated to reach 937,000 within 15 years.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact